Medicenna Therapeutics Corp Stock Today
| MDNA Stock | CAD 0.99 0.01 1.00% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Medicenna Therapeutics is selling at 0.99 as of the 25th of March 2025; that is 1% down since the beginning of the trading day. The stock's open price was 1.0. Medicenna Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. MEDICENNA THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. The company has 78.22 M outstanding shares of which 56.51 K shares are now shorted by private and institutional investors with about 0.87 days to cover all short positions. More on Medicenna Therapeutics Corp
Moving together with Medicenna Stock
Moving against Medicenna Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Medicenna Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Medicenna Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Medicenna Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Medicenna Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Medicenna Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsMedicenna Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Medicenna Therapeutics' financial leverage. It provides some insight into what part of Medicenna Therapeutics' total assets is financed by creditors.
| |||||
Medicenna Therapeutics Corp (MDNA) is traded on Toronto Exchange in Canada and employs 16 people. Medicenna Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 77.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medicenna Therapeutics's market, we take the total number of its shares issued and multiply it by Medicenna Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Medicenna Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 78.22 M outstanding shares of which 56.51 K shares are now shorted by private and institutional investors with about 0.87 days to cover all short positions.
Medicenna Therapeutics Corp has accumulated about 33.6 M in cash with (16.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83.
Check Medicenna Therapeutics Probability Of Bankruptcy
Ownership AllocationMedicenna Therapeutics maintains a total of 78.22 Million outstanding shares. Medicenna Therapeutics Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Medicenna Ownership Details
Medicenna Therapeutics Risk Profiles
Although Medicenna Therapeutics' alpha and beta are two of the key measurements used to evaluate Medicenna Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.82 | |||
| Standard Deviation | 3.61 | |||
| Variance | 13.04 | |||
| Risk Adjusted Performance | (0.20) |
Medicenna Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Medicenna Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Medicenna Therapeutics Corporate Management
Elected by the shareholders, the Medicenna Therapeutics' board of directors comprises two types of representatives: Medicenna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medicenna. The board's role is to monitor Medicenna Therapeutics' management team and ensure that shareholders' interests are well served. Medicenna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medicenna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fahar Merchant | Chairman, Founder | Profile | |
| MBBS MD | Acting Devel | Profile | |
| MD FCAP | Chief Officer | Profile | |
| CBV CA | Chief Officer | Profile | |
| Samuel MD | Scientific Advisor | Profile |
Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.